决明子提取物对高脂血症大鼠血脂和肝肾功能的影响

doi:10.19485/j.cnki.issn2096-5087.2021.12.025

Preventive Medicine

2021, Vol. 33

Issue (12): 1290-1294 DOI: 10.19485/j.cnki.issn2096-5087.2021.12.025

Laboratory Research

Current Issue | Archive | Adv Search

Effect of extracts of Cassiae Semen on lipid, liver and kidney function in hyperlipidemia rats

ZHU Zhoujing, ZHANG Shixin, ZHENG Yunyan, et al

Abstract
Figure/Table
References
Related Citation (0)

[1] 中华人民共和国国家药典委员会.中华人民共和国药典(一部)[S].北京:中国医药科技出版社,2020.
[2] 葛肖波,薛晓琳,李鑫,等.基于现代文献探讨干预血脂异常的药食同源类药物用药特点及其病机分析[J].世界中西医结合杂志,2020,15(5):845-849.
[3] 董玉洁,蒋沅岐,刘毅,等.决明子的化学成分、药理作用及质量标志物预测分析[J].中草药,2021,52(9):2719-2732.
[4] SHEN T,LIU Y X,SHANG J,et al.Incidence and etiology of drug-induced liver injury in mainland China[J].Gastroenterology,2019,156(8):2230-2241.
[5] HEISEL T,MONTASSIER E,JOHNSON A,et al.High-fat diet changes fungal microbiomes and interkingdom relationships in the murine gut[J].mSphere,2017,2(2017-10-11)[2021-09-14].https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5636226.DOI:10.1128/mSphere.00351-17.
[6] 刘飞,郭换,梁乙川,等.基于降血脂功效的决明子安全性评价[J].中国实验方剂学杂志,2017,23(17):183-189.
[7] 赵艺萌,吴丽,张烁,等.决明子的安全性评价与风险控制措施的探讨[J].中国中药杂志,2017(21):34-38.
[8] 张荣,冯玛莉,武玉鹏,等.决明子降血脂有效部位及其量效关系的实验研究[J].中国药物与临床,2005,5(3):183-185.
[9] 张加雄,万丽,胡轶娟,等.决明子降血脂有效部位的研究[J].时珍国医国药,2006,17(6):904-905.
[10] 许鹏飞,孙学斌,黄尹琦,等.决明子降脂有效成分的研究进展[J].中华中医药学刊,2018,36(1):150-153.
[11] 郭换,李峰庆,杨昌林,等.决明子水煎剂降低营养性高脂血症大鼠血脂量效关系研究[J].中药药理与临床,2017,33(5):94-98.
[12] MENG Y Y,LIU Y,FANG N N,et al.Hepatoprotective effects of Cassia semen ethanol extract on non-alcoholic fatty liver disease in experimental rat[J].Pharm Biol,2019,57(1):98-104.
[13] 葛俊德,黄娜娜,郭欣,等.不同提取工艺对炒决明子急性毒性和物质基础的影响[J].中国药物警戒,2019,42(4):641-647.
[14] YANG J L,ZHU A,XIAO S,et al.Anthraquinones in the aqueous extract of Cassiae semen cause liver injury in rats through lipid metabolism disorder[J/OL].Phytomedicine,2019,64[2021-09-14].https://doi.org/10.1016/j.phymed.2019.153059.
[15] XU L L,LI J,TANG X L,et al.Metabolomics of aurantio-obtusin-induced hepatotoxicity in rats for discovery of potential biomarkers[J/OL].Molecules,2019,24(2019-09-23)[2021-09-14].https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6804130.DOI:10.3390/molecules24193452.
[16] FUJIWARA R,HAAG M,SCHAEFFELER E,et al.Systemic regulation of bilirubin homeostasis:potential benefits of hyperbilirubinemia[J].Hepatology,2018,67(4):1609-1619.
[17] BORÉN J,CHAPMAN M J,KRAUSS R M,et al.Low-density lipoproteins cause atherosclerotic cardiovascular disease:pathophysiological,genetic,and therapeutic insights:a consensus statement from the European Atherosclerosis Society Consensus Panel[J].Eur Heart J,2020,41(24):2313-2330.